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Dr Sakr and colleagues [1] report a single centre cohort 
study evaluating the relationship between anaemia, blood 
transfusions and mortality in patients admitted to a 
surgical ICU. Th   e authors report some ﬁ  ndings that are 
not new or surprising, namely that anaemia is associated 
with adverse patient outcomes. However, when they 
performed multivariate analyses with adjustment for 
potential confounders to the blood transfusion/patient 
outcomes relationship they found that transfusions were 
associated with lower patient mortality, especially among 
older sicker patients. At face value this contradicts the 
majority of previous cohort studies [2] and the only large 
randomised trial of diﬀ   erent transfusion triggers in 
critically ill patients (the Canadian Critical Care Trials 
Group’s ‘Transfusion requirements in critical care’ 
(TRICC) trial) [3]. Th   e authors’ ﬁ  ndings raise a number 
of questions, including: does this association indicate 
cause and eﬀ  ect’? Are the ﬁ  ndings of the TRICC trial 
generalisable to intensive care patients today? And, 
perhaps most importantly, should we use blood more 
liberally in critically ill patients than the TRICC trial and 
our current guidelines suggest?
Does this association indicate ‘cause and eff  ect’?
Although it is possible to perform complex statistical 
adjustments for potential confounders in cohort studies 
to try to clarify the true relationship between a variable 
or intervention of interest and an outcome, this is 
notoriously problematic, especially in relation to blood 
transfusions [4]. Adjustments can be made for measured 
factors, but there is always the possibility of residual 
confounding from ‘unknowns’, which is more likely in 
complex heterogeneous populations. ICU populations 
are highly heterogeneous at multiple levels, including 
pre-illness co-morbidity, diagnosis requiring admission, 
early illness severity, and subsequent complications, to 
name a few. Dr Sakr and colleagues included adjustment 
for some factors but, as they acknowledge, it is very likely 
there were many ‘unknowns’ that were potentially rele-
vant. Bias by indication is very likely in this sort of 
analysis whereby factors aﬀ  ecting a clinical decision (blood 
transfusion in this case) cannot be adequately captured 
or adjusted for, thereby introducing an imbalance. Dr 
Sakr and colleagues used propensity analysis in an 
attempt to overcome this problem, which attempts to 
produce matched pairs from observational data to 
simulate a ‘virtual’ randomised trial. Th  e limitations of 
this approach have been previously discussed in detail in 
relation to another cohort study involving some of these 
authors [5,6]. Although the chance of erroneous asso-
ciations is probably reduced, the problem remains that 
the patients being matched may diﬀ  er in unmeasured 
ways. Th   is might be more likely in a single centre study, 
such as the one performed by Dr Sakr and colleagues, 
where transfusion decision-making was presumably 
more consistent. Th  e mean hemoglobin transfusion 
trigger was 8.2 g/dL and in 30% of cases it was >9 g/dL, so 
this ICU was signiﬁ  cantly more liberal than the restrictive 
arm of the TRICC trial [3]. Another issue is that there 
was no information about the indications for transfusion, 
especially bleeding, which could have created imbalance 
between the matched pairs. In short, we cannot be sure 
of causality between blood transfusions and better 
outcomes, but the study does stimulate us to look again 
at the TRICC trial and its relevance today.
Abstract
Current evidence suggests that critically ill patients 
tolerate anaemia well and that blood transfusions 
may increase the risk of adverse outcomes. Dr Sakr 
and colleagues present a contradictory analysis of a 
surgical ICU cohort, fi  nding an association between 
blood transfusions and lower hospital mortality after 
adjustment for a range of potential confounders. 
Analyses of this kind are interesting and provocative, 
but are limited by residual confounding and bias by 
indication. The data emphasise the need for additional 
high quality trials of transfusion practice in critical care.
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intensive care patients today?
Th  e TRICC trial found that mortality was higher in 
younger patients (aged <55  years) and those with 
APACHE II scores <20 when blood was used liberally [3]. 
Treatment eﬀ   ects were similar for older patients and 
those with APACHE II scores ≥20, and in subgroup 
analyses no strong signals favouring either group were 
found in relation to duration of mechanical ventilation 
[7], or trauma diagnosis [8]. Patients with ischemic heart 
disease as a baseline comorbidity had a trend towards 
better outcome with more liberal blood use [9] and a 
later analysis highlighted the potential interaction 
between ischemic heart disease and the hemoglobin level 
maintained in intensive care, which could have been 
underestimated in the original trial report [10]. All of 
these subgroup analyses were underpowered, and even 
the full trial was much smaller than intended (the 
intended sample size was 1,620; achieved was 838). 
Another relevant factor was that clinicians declined to 
enrol 29% of eligible patients. Th  ese issues raise the 
possibility that diﬀ  erent treatment eﬀ  ects might exist for 
patients with ischemic heart disease, and among older 
and/or sicker patients, especially those with evidence of 
inadequate oxygen delivery or delayed weaning from 
mechanical ventilation. Th   ese uncertainties are acknow-
ledged in recent guidelines and systematic reviews 
[11,12], and it is perhaps not surprising that surveys 
indicate continued variation in clinical practice [11,13]. 
Th  e other key uncertainty relates to the impact of pre-
storage leucodepletion, which was not used during the 
TRICC trial, but is now undertaken routinely in most 
developed countries. Th   is additional processing step was 
associated with small (1% absolute risk reduction) but 
signiﬁ  cant ICU mortality reduction in Canada, and may 
be particularly important with prolonged red cell storage 
[14,15].
Should we use blood more liberally in critically 
ill patients than the TRICC trial and our current 
guidelines suggest?
Th  e answer to this question for younger, less severely 
unwell patients is surely NO. For other patients we need 
to continue to use clinical judgement, but the evidence is 
still most consistent with a target haemoglobin concen-
tration of <9 g/dL, especially given the potential risks of 
blood transfusions and uncertain eﬀ  ectiveness of stored 
red cells [11,15]. Given our recent experiences of thera-
peutic strategies with early promise, but for which later 
trials showed conﬂ  icting safety data either overall (for 
example, tight glycaemic control) or in patient subgroups 
(for example, activated protein C), it is surely time for a 
‘new TRICC’. Only well designed randomised trials will 
improve our conﬁ  dence in making transfusion decisions. 
Unfortunately, studies such as the one performed by Dr 
Sakr and colleagues simply add to our uncertainty.
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